Recruiting Amyloidosis Studies in Sacramento
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patient...
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL)....
About Amyloidosis Clinical Trials in Sacramento
Amyloidosis is a group of diseases in which abnormal proteins (amyloids) build up in organs and tissues, impairing their function. Types include AL, AA, and ATTR amyloidosis. Treatment depends on the type and may include chemotherapy, organ transplant, or targeted therapies.
There are currently 2 amyloidosis clinical trials recruiting participants in Sacramento, CALIFORNIA. These studies are seeking a combined 240 participants. Research is being sponsored by Alnylam Pharmaceuticals, Nexcella Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Amyloidosis Clinical Trials in Sacramento — FAQ
Are there amyloidosis clinical trials in Sacramento?
Yes, there are 2 amyloidosis clinical trials currently recruiting in Sacramento, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Sacramento?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Sacramento research site will contact you about next steps.
Are clinical trials in Sacramento free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Sacramento studies also compensate for your time and travel.
What amyloidosis treatments are being tested?
The 2 active trials in Sacramento are testing new therapies including novel drugs, biologics, and treatment approaches for amyloidosis.
Data updated March 2, 2026 from ClinicalTrials.gov